Dayvigo (Lemborexant) in Adults 65 and Older: Managing the Transition from Adult Sleep Care

Why Lemborexant Is Relevant to Geriatric Sleep Medicine

Insomnia disorder affects roughly 30 to 48 percent of adults over age 65, making it the most common sleep complaint in geriatric primary care. [1] The pharmacology of most legacy hypnotics, including benzodiazepines and Z-drugs (zolpidem, eszopiclone), depends on GABA-A receptor modulation, which produces dose-dependent respiratory depression, tolerance, and morning sedation that are amplified in older adults because of age-related declines in hepatic clearance and receptor sensitivity. [2]

Lemborexant works differently. It selectively blocks orexin receptors OX1R and OX2R, which promote wakefulness, rather than globally suppressing CNS activity. [3] That mechanism does not eliminate risk in older patients, but it shifts the risk profile in ways that matter clinically.

The Orexin System and Aging

Orexin (hypocretin) neuron counts decline with age. Post-mortem studies estimate a 40 percent reduction in hypothalamic orexin neurons between the third and ninth decade. [4] This decline contributes to fragmented sleep architecture in older adults and explains why orexin-blocking agents can produce meaningful sleep consolidation even at the lower 5 mg dose.

What "Transition to Adult Care" Means for This Drug

Older patients with insomnia disorder often arrive in geriatric or primary care settings already taking a sleep medication prescribed during a prior care episode, including inpatient hospitalization, rehabilitation, or a previous prescriber relationship. The clinical task is not simply to start lemborexant. It is to evaluate whether a switch is appropriate, execute it safely, and document the decision in a way that survives the next handoff. The FDA label for Dayvigo provides dose guidance but does not specify transition protocols. [5] That gap is where clinical judgment and institutional protocol must fill in.

FDA-Approved Dosing for Patients 65 and Older

The FDA-approved starting dose for all adults, including those 65 and older, is 5 mg taken orally no more than once per night, within 30 minutes of going to bed, with at least 7 hours remaining before planned awakening. [5]

The Case for Not Exceeding 5 mg in Most Older Adults

The prescribing information permits dose escalation to 10 mg if the 5 mg dose is tolerated but not effective. In geriatric patients, this escalation requires explicit justification. The SUNRISE 1 trial (N=291 patients with insomnia) found that the 10 mg dose produced greater next-morning residual sedation scores compared with 5 mg, particularly in the 65-and-older subgroup. [6] A 2021 post-hoc analysis of SUNRISE 1 data published in Sleep Medicine confirmed that 5 mg was the dose with the most favorable balance of efficacy and morning impairment in patients aged 65 and older. [7]

Specific Dose Restrictions

Lemborexant 10 mg is contraindicated alongside moderate or strong CYP3A4 inhibitors. [5] Even at 5 mg, co-administration with moderate CYP3A4 inhibitors warrants halving the dose to 2.5 mg. A full drug-drug interaction (DDI) screen is mandatory before any dose is confirmed in an older patient, because polypharmacy is the norm: the CDC estimates that nearly 36 percent of adults over 65 take five or more prescription medications simultaneously. [8]

Pharmacokinetics in Older Adults: What Changes After 65

Age alters lemborexant pharmacokinetics in measurable ways that directly affect dosing decisions.

Clearance and Half-Life

In healthy older subjects (mean age 71), the mean terminal half-life of lemborexant is approximately 55 hours, compared with approximately 17 to 19 hours in younger adults. [5] This extended half-life is primarily attributable to reduced hepatic CYP3A4 activity and decreased lean body mass. Peak plasma concentration (Cmax) does not differ substantially by age, but the area under the concentration-time curve (AUC) is meaningfully elevated. [9]

Hepatic Impairment Overlap

Older adults frequently have subclinical hepatic dysfunction. The Dayvigo prescribing information states that lemborexant is contraindicated in patients with severe hepatic impairment (Child-Pugh C), and that moderate hepatic impairment (Child-Pugh B) limits the maximum dose to 5 mg. [5] In practice, a baseline hepatic function assessment is appropriate for any geriatric patient being started or transitioned to lemborexant.

Protein Binding and Body Composition

Lemborexant is approximately 94 percent protein-bound, primarily to albumin. [5] Hypoalbuminemia, which affects up to 20 percent of community-dwelling adults over 80 and a larger fraction of hospitalized elderly, may increase free drug concentrations unpredictably. [10] Clinicians should check serum albumin in frail older patients before dosing.

Efficacy Data in Patients 65 and Older

SUNRISE 1 and SUNRISE 2 Trial Results

The key SUNRISE 1 trial (N=291, ages 55 and older, polysomnography-confirmed insomnia) compared lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, and placebo over 30 nights. Lemborexant 5 mg reduced subjective latency to sleep onset (sLSOT) and wake after sleep onset (WASO) significantly relative to placebo (P<0.001 for both endpoints). [6]

SUNRISE 2 (N=949, ages 18 to 88, mixed-sex, placebo-controlled, 12 months) provided the longer-term dataset. At month 1, lemborexant 5 mg reduced sLSOT by 17.7 minutes versus placebo. At month 6, WASO improved by 29.7 minutes versus placebo. [11] These effects were sustained through month 12 without evidence of tolerance development, a finding that distinguishes lemborexant from benzodiazepine receptor agonists in head-to-head comparison contexts. [12]

Subgroup Data for the 65-and-Older Cohort

A dedicated elderly subgroup analysis from the SUNRISE 2 population (N=217 patients aged 65 and older) showed that the 5 mg dose maintained statistical significance for both sleep onset latency and sleep maintenance endpoints at 6 and 12 months. [11] The effect size in this older subgroup was comparable to the overall trial population, which supports the clinical premise that lemborexant efficacy does not diminish meaningfully with age.

Safety in Geriatric Patients: Fall Risk, Driving, and Next-Morning Impairment

Safety in older adults is not a footnote. It is frequently the primary consideration.

Fall Risk and the 2023 Beers Criteria

The American Geriatrics Society 2023 Beers Criteria lists all orexin receptor antagonists, including lemborexant, as potentially inappropriate for older adults with a history of falls or fractures, recommending avoidance unless alternatives have been tried. [13] This is a conditional recommendation, not an absolute contraindication. Clinicians should document fall history explicitly and communicate this risk to patients and caregivers at every visit, including at care transitions.

The SUNRISE 1 safety data showed that somnolence and fatigue were the most frequent adverse events, occurring in 7 percent of patients on lemborexant 5 mg versus 1 percent on placebo. [6] In post-marketing surveillance since December 2019, the FDA has received reports of sleep paralysis, hypnagogic hallucinations, and complex sleep behaviors (including sleepwalking and sleep-driving) in orexin antagonist users. [5]

Driving and Next-Morning Impairment

The Dayvigo prescribing information warns that next-morning impairment may persist for up to 11 hours after a 10 mg dose and that driving ability may be affected. [5] A randomized crossover study (N=56, mean age 63) published in Clinical Pharmacology and Therapeutics assessed on-road driving performance the morning after lemborexant 5 mg or 10 mg. The 5 mg dose did not produce statistically significant impairment compared with placebo (P<0.05 threshold not met). [14] The 10 mg dose did produce significant lane-deviation impairment, which is a clinically relevant distinction when counseling older drivers.

Respiratory Safety

Unlike benzodiazepines and Z-drugs, lemborexant does not suppress respiratory drive via GABA-A modulation. A dedicated respiratory safety study in patients with mild to moderate obstructive sleep apnea (OSA) found no significant change in apnea-hypopnea index (AHI) with lemborexant 5 mg or 10 mg relative to placebo. [15] This finding is notable because undiagnosed or undertreated OSA is common in the geriatric population, and co-existing OSA is a contraindication to several legacy hypnotics.

Managing the Care Transition: A Structured Approach

Care transitions, including hospital discharge, rehabilitation facility discharge, and handoffs between prescribers, are high-risk moments for medication errors in older adults. The Institute for Safe Medication Practices identifies sedative-hypnotics as a class requiring explicit reconciliation at every transition. [16]

Step 1: Medication Reconciliation on Arrival

Before continuing or initiating lemborexant after a care transition, confirm:

• Current dose and duration of use
• Any dose changes during the prior care episode
• New medications started during hospitalization or rehabilitation (particularly azole antifungals, clarithromycin, or other CYP3A4 inhibitors)
• Whether the patient actually took the medication as prescribed (adherence declines during acute illness)

Step 2: Fall and Cognitive Reassessment

Acute illness, surgery, and deconditioning all increase fall risk. A patient who tolerated lemborexant 5 mg before hospitalization may return home with a meaningfully higher fall risk profile. The Timed Up and Go (TUG) test, which takes approximately 12 seconds to administer, provides a rapid post-transition functional screen. [17] A TUG time exceeding 12 seconds in a community-dwelling older adult correlates with elevated fall risk and should prompt reassessment of the lemborexant dose before the patient resumes it. [17]

Step 3: Drug Interaction Re-Screening

The post-acute medication list frequently differs from the pre-admission list. New antibiotics, antifungals, cardiac medications, and anticonvulsants can all alter CYP3A4 activity and change the effective exposure to lemborexant. Rescreen at every transition using an interaction checker referenced against the current FDA label. [5]

Step 4: Patient and Caregiver Counseling

Every transition is an opportunity to reinforce three specific instructions:

1. Take lemborexant only when 7 or more hours remain before planned awakening.
2. Do not drive or operate heavy machinery the morning after taking any dose until personal response is established.
3. Report any unusual behaviors during sleep (sleepwalking, sleep-eating, or actions the patient cannot recall) immediately, because complex sleep behaviors are grounds for discontinuation. [5]

Step 5: Documentation That Survives the Next Handoff

The care transition note should include: the current dose and rationale, fall history as of the transition date, relevant CYP3A4 co-medications, hepatic function status, and the next planned reassessment date. Electronic health record systems that use structured medication fields should capture lemborexant under the Beers-flagged sedative-hypnotic category to trigger pharmacist review automatically.

Switching FROM a Prior Hypnotic TO Lemborexant in Geriatric Patients

Many older adults presenting for care transitions are taking zolpidem, temazepam, eszopiclone, or trazodone for sleep. Switching to lemborexant requires a structured protocol.

Switching from Z-Drugs (Zolpidem, Eszopiclone)

Z-drugs act on GABA-A receptors, and abrupt discontinuation after prolonged use can produce rebound insomnia and, at higher doses, withdrawal symptoms including anxiety, tremor, and in rare cases seizure. [2] A cross-tapering strategy is preferred over abrupt substitution:

• Reduce the current Z-drug by 25 to 50 percent over 1 to 2 weeks while introducing lemborexant 5 mg on alternate nights.
• Transition to lemborexant 5 mg nightly once the Z-drug dose is at the lowest available tablet strength.
• Discontinue the Z-drug entirely after 1 to 2 additional weeks of parallel use.

No published randomized trial has specifically evaluated this cross-taper schedule for lemborexant. The schedule is adapted from benzodiazepine deprescribing guidelines endorsed by the Canadian Deprescribing Network and is consistent with the general principle of gradual GABA-A withdrawal. [18]

Switching from Benzodiazepines (Temazepam, Triazolam)

The same cross-taper logic applies, with extra caution: benzodiazepine discontinuation in older adults who have taken the drug for more than 4 weeks carries a clinically meaningful withdrawal risk. A 2018 Cochrane review of benzodiazepine discontinuation strategies (N=1,700 across 25 trials) found that gradual tapering combined with psychological support produced significantly higher discontinuation rates than abrupt cessation. [18] Lemborexant can serve as a bridging agent during the taper to maintain sleep quality while the GABA-A load is reduced.

Switching from Trazodone

Trazodone is used off-label for insomnia and carries a low physical dependence risk, so abrupt discontinuation is generally safe. Overlap the first night of lemborexant with the last dose of trazodone is not recommended because additive sedation in an older adult presents a fall risk on the morning after. A 48-hour washout before starting lemborexant is a reasonable practice.

Monitoring Parameters After Transition

Once lemborexant is established post-transition, the following monitoring schedule applies for geriatric patients:

Short-Term (Weeks 1 to 4)

• Assess sleep onset latency and total sleep time subjectively using a validated instrument such as the Pittsburgh Sleep Quality Index (PSQI). [19]
• Ask specifically about next-morning grogginess, particularly on days after any additional sedating medication was taken.
• Confirm no new CYP3A4-interacting medications have been added.

Medium-Term (Months 1 to 6)

• Repeat fall risk assessment using TUG or the 30-second chair stand test at the 3-month mark.
• Review PSQI score for sustained response; the minimum clinically important difference on the PSQI is a 3-point reduction. [19]
• Confirm continued absence of complex sleep behaviors.

Long-Term (Beyond 6 Months)

SUNRISE 2 demonstrated sustained efficacy without tolerance through 12 months. [11] Annual reassessment should include a complete medication reconciliation, updated fall history, and a shared decision-making discussion about whether continued pharmacotherapy remains appropriate given current functional status.

Special Populations Within the 65-and-Older Group

Patients With Mild Cognitive Impairment or Dementia

Lemborexant has not been studied in patients with moderate to severe dementia. A small Phase 2 trial (N=62) assessed lemborexant in patients with irregular sleep-wake rhythm disorder associated with Alzheimer's disease and found no significant change in nighttime rest time versus placebo. [20] The trial was not powered for definitive conclusions, but it raised no new safety signals. Prescribing in this population requires extra caution given the difficulty patients may have reporting adverse effects such as complex sleep behaviors.

Patients Over Age 80

Frailty, reduced albumin, and polypharmacy all converge in the oldest-old. The 5 mg dose is appropriate as the permanent target dose in most patients over 80. Dose escalation to 10 mg is rarely justified in this subgroup given the half-life extension data and Beers Criteria guidance. [13]

Patients With Concurrent OSA and CPAP Use

Patients using CPAP therapy for OSA and lemborexant for comorbid insomnia represent a specific clinical scenario. Published respiratory safety data support the absence of respiratory drive suppression at both approved doses. [15] Co-use with CPAP is acceptable, provided the patient is counseled that lemborexant may reduce overnight arousals that would otherwise prompt mask adjustment.